Articoli con mandati relativi all'accesso pubblico - J.F. MannUlteriori informazioni
Non disponibili pubblicamente: 8
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised …
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with ...
The Lancet 372 (9644), 1174-1183, 2008
Mandati: Canadian Institutes of Health Research
Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial
JFE Mann, C Anderson, P Gao, HC Gerstein, M Boehm, L Ryden, ...
Journal of hypertension 31 (2), 414-421, 2013
Mandati: Heart and Stroke Foundation of Canada
Diet and major renal outcomes: a prospective cohort study. The NIH-AARP Diet and Health Study
A Smyth, M Griffin, S Yusuf, JFE Mann, D Reddan, M Canavan, J Newell, ...
Journal of Renal Nutrition 26 (5), 288-298, 2016
Mandati: Health Research Board, Ireland
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
JFE Mann, P Joseph, P Gao, P Pais, J Tyrwhitt, D Xavier, T Dans, ...
Kidney International 103 (2), 403-410, 2023
Mandati: Wellcome Trust
Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke
M Boehm, H Schumacher, KK Teo, EM Lonn, L Lauder, G Mancia, ...
Journal of Hypertension 39 (8), 1602-1610, 2021
Mandati: German Research Foundation, UK Medical Research Council, National Institute …
Correspondence (letter to the editor): an experimental procedure paid for by the general public
J Mann, K Hilgers, R Veelken, F Luft
Deutsches Ärzteblatt International 109 (17), 311, 2012
Mandati: German Research Foundation
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Front. Pharmacol. 13: 786767. doi: 10.3389 …
SC Tye, ST de Vries, JFE Mann, M Schechter, O Mosenzon, P Denig, ...
Frontiers in Pharmacology| www. frontiersin. org 13, 2022
Mandati: Netherlands Organisation for Scientific Research, European Commission
Treatment Strategies for Resistant Arterial Hypertension.
A Chandra, M Kütemeyer, J Mann, K Hilgers, R Veelken, F Luft, CA Koch, ...
Deutsches Ärzteblatt International 109 (17), 2012
Mandati: German Research Foundation
Disponibili pubblicamente: 56
Liraglutide and cardiovascular outcomes in type 2 diabetes
SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ...
New England Journal of Medicine 375 (4), 311-322, 2016
Mandati: US National Institutes of Health
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ...
The Lancet 382 (9889), 339-352, 2013
Mandati: US National Institutes of Health
Liraglutide and renal outcomes in type 2 diabetes
JFE Mann, DD Ørsted, K Brown-Frandsen, SP Marso, NR Poulter, ...
New England Journal of Medicine 377 (9), 839-848, 2017
Mandati: US National Institutes of Health
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts
RT Gansevoort, K Matsushita, M Van Der Velde, BC Astor, M Woodward, ...
Kidney international 80 (1), 93-104, 2011
Mandati: US National Institutes of Health
Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies
A Mente, M O'Donnell, S Rangarajan, G Dagenais, S Lear, M McQueen, ...
The Lancet 388 (10043), 465-475, 2016
Mandati: Canadian Institutes of Health Research, Genome Canada, Heart and Stroke …
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
M Böhm, H Schumacher, KK Teo, EM Lonn, F Mahfoud, JFE Mann, ...
The Lancet 389 (10085), 2226-2237, 2017
Mandati: German Research Foundation, UK Medical Research Council, National Institute …
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
CM Clase, JJ Carrero, DH Ellison, ME Grams, BR Hemmelgarn, ...
Kidney international 97 (1), 42-61, 2020
Mandati: US National Institutes of Health
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left …
JJV McMurray, DL DeMets, SE Inzucchi, L Køber, MN Kosiborod, ...
European journal of heart failure 21 (5), 665-675, 2019
Mandati: US National Institutes of Health
Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease
AK Cheung, TI Chang, WC Cushman, SL Furth, FF Hou, JH Ix, GA Knoll, ...
Kidney international 99 (3), 559-569, 2021
Mandati: US National Institutes of Health, American Heart Association, Canadian …
KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease
AK Cheung, TI Chang, WC Cushman, SL Furth, FF Hou, JH Ix, GA Knoll, ...
Kidney International 99 (3), S1-S87, 2021
Mandati: US National Institutes of Health
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved …
SD Anker, J Butler, GS Filippatos, W Jamal, A Salsali, J Schnee, K Kimura, ...
European journal of heart failure 21 (10), 1279-1287, 2019
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake
M O’Donnell, A Mente, MH Alderman, AJB Brady, R Diaz, R Gupta, ...
European heart journal 41 (35), 3363-3373, 2020
Mandati: European Commission
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software